Anti-cancer compounds

Details Anti-cancer compounds Anti-cancer compounds

2004-07-22

2008-08-12

Tate, Christopher R. (Department: 1655)

Drug, bio-affecting and body treating compositions

Plant material or plant extract of undetermined constitution...

C424S195180, C514S675000, C514S691000, C514S729000, C514S738000

Reexamination Certificate

active

07410656

ABSTRACT:
This invention relates to a compound or group of compounds present in an active principle derived from plants of speciesEuphorbia peplus, Euphorbia hirtaandEuphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, andpharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.

REFERENCES:
patent: 4418064 (1983-11-01), Powell et al.
patent: 4560774 (1985-12-01), Pettit et al.
patent: 4716179 (1987-12-01), Hecker et al.
patent: 5145842 (1992-09-01), Driedger et al.
patent: 5643948 (1997-07-01), Driedger et al.
patent: 5716968 (1998-02-01), Driedger et al.
patent: 5750568 (1998-05-01), Driedger et al.
patent: 5886017 (1999-03-01), Driedger et al.
patent: 5886019 (1999-03-01), Driedger et al.
patent: 5891870 (1999-04-01), Driedger et al.
patent: 5891906 (1999-04-01), Driedger et al.
patent: 5932613 (1999-08-01), Jiang et al.
patent: 6268395 (2001-07-01), Hattori
patent: 6432452 (2002-08-01), Aylward
patent: 6593371 (2003-07-01), Staggs
patent: 6787161 (2004-09-01), Aylward
patent: 6844013 (2005-01-01), Aylward
patent: 2003/0166613 (2003-09-01), Aylward et al.
patent: 2003/0171334 (2003-09-01), Aylward et al.
patent: 2003/0171337 (2003-09-01), Aylward et al.
patent: 2003/0195168 (2003-10-01), Aylward et al.
patent: 2005/0003031 (2005-01-01), Aylward et al.
patent: 2005/0209192 (2005-09-01), Aylward et al.
patent: 2006/0105994 (2006-05-01), Aylward
patent: 1077129 (1993-10-01), None
patent: 1105246 (1995-07-01), None
patent: 1112011 (1995-11-01), None
patent: 1131037 (1996-09-01), None
patent: 29 02 506 (1979-01-01), None
patent: 41 02 054 (1992-07-01), None
patent: 0 330 094 (1989-08-01), None
patent: 0 455 271 (1991-11-01), None
patent: 0 310 622 (1992-04-01), None
patent: 8-13571 (1996-01-01), None
patent: 8-176002 (1996-07-01), None
patent: 08-245505 (1996-09-01), None
patent: 8-245505 (1996-09-01), None
patent: WO 87/07599 (1987-12-01), None
patent: WO 97/15575 (1997-05-01), None
Zayed et al. J. Cancer Res. Clin. Oncol. 1998 vol. 124, pp. 301-306.
Abo, K.A. Fitoterapia. 1988. vol. LIX, No. 3, pp. 244-246.
Valente et al. Planta Med. 2003. vol. 69, pp. 361-366.
M. Belkin et al.;Tumor-Damaging Capacity of Plant materials. I. Plants Used asCathartics, Natl. Cancer Inst., 13, Apr. 7, 1952, pp. 139-149.
D. Weedon et al.,Home Treatment of Basal Cell Carcinoma, Med. J. Aust., 1, Jun. 12, 1976, p. 928.
J. Jakupovic et al., “Diterpenes fromEuphorbia peplus” Phytochemistry, vol. 47, pp. 1601-1699 (1998).
M. Belkin et al., “Tumor-Damaging Capacity of Plant Materials”.I. Plants Used as Cathartics, National. Cancer Institute., 13: 139-149 (1952).
D. Weedon et al., “Home Treatment of Basal Cell Carcinoma”,Med. J. Aust., 1: 928 (1976).
Uemura, D.. et al., “New Diterpene, 13-Oxyingenol, Derivative Isolated from Euphorbia Kansui Liou”,Tetrahedron Letters29:2529-2532 (1974).
Kupchan S.M. et al., “Antileukemic Principles Isolated From Euphorbiaceae Plants”Science, 191: 571-572 (1975).
Kupchan S.M. et al., “Gnidimacrin and Gnidimacrin 20-Palmitate, Novel Macrocyclic Antileukemic Diterpenoid Esters FromGnidia subcordata”, Communications to theEditor: 5719-5720 (1976).
Evans, F.J. et al., “The Tigliance, Daphane and Ingenane Diterpenes, Their Chemistry, Distribution and Biological Activities, A Review.”Lloydia41(3): 193-233 (1978).
Hecker E., “Structure-Activity Relationships in Diterpene Esters Irritant and Cocarcinogenic to Mouse Skin”,Carcinogenesis2: 11-48 (1978).
Seip E.H. et al., “Skin Irritant Ingenol Esters fromEuphorbia Esula” , Planta Medica46: 215-218 (1982).
Nishizuka Y., “The Role of Protein Kinase C in Cell Surface Signal Tranduction and Tumour Promotion”,Nature308:693-698 (1984).
Schmidt R.J., “The Ingenane Polyol Esters”,Naturally Occurring Phorbol Esters, Boca Raton: CRC Press: 245-269 (1986).
Inoue S. et al., “Ingenane Synthetic Studies. Sterocontrolled Introduction Of All Oxygenated And Unsaturated Centers In An Ingenol Prototype”,J. Org. Chem. 52:5497-5498 (1987).
Hamamoto Y. et al., “Comparison of Effects of Protein Kinase C Inhibitors on Phorbol Ester-Induced CD4 Down-Regulation and Augmentation of Human Immunodeficiency Virus Replication In Human Cell Lines”,Biochemical and Biophysical Research Communications 164(1): 339-344 (1989).
Chowdhury I.H. et al., The Phorbol Ester TPA Strongly Inhibits HIV-1-Induced Syncytia Formation but enhances Virus Production: Possible Involvement of Protein Kinase C Pathway,Virology176: 126-132 (1990).
Laurence J. et al., “Phorbol Ester-Mediated Induction of HIV-1 from A Chronically Infected Promonocyte Clone: Blockade by Protein Kinase Inhibotors and Relationship to Tat-Directed Trans-Activation”,Biochemical and Biophysical Research Communications166(1): 349-357 (1990).
Krauter, et al., “Structure/activity relationships of polyfunctional diterpenes of tigliane type”Eur. J. Biochem, 242: 417-427 (1996).
El-Merzabani, et al., “Screening System for Egyptian Plants with Potential Anti-tumour Activity”,Planta Medica.36: 150-155 (1979).
Benjamini, El et al. “Immunology”—A Short Course: 15-18 (1988).
Abo, K.A. “Fitoterpia”, LIX(3): 244-246 (1988).
Alastair Aitken et al., “The Activation of Protein Kinase C by Daphnane, Ingenane and Tigliane Diterpenoid Esters”,Botanical Journal of the Linnean Society, 94: 247-263 (1987).
Evans, F.J. et al., “Pro-Inflammatory, Tumor-Promoting and Anti-Tumor Diterpenes of the Plant Families Euphoribiaceae and Thymelaeaceae”Department of Pharmacognosy, The School of Pharmacy, University of London, 44: 90-99, 1986.
Tian-Shung Wu et al., “Antitumor Agents, 1191Kansuiphorins A and B, Two Novel Antileukemic Diterpene Esters From Euphorbia Kansui”,Journal of Natural Products, 54(3): 823-829 (1991).
Salah M.A.D. Zayed et al., “Dietary cancer risk from conditional cancerogens in produce of livestock fed on species of spruge (Euphorbiaceae) I. Skin irritant and tumor promoters of the ingenane diterpene ester type”,Cancer Res. Clin. Oncol, 124: 131-140 (1998).
B D Curti “Physical Barriers to Drug Delivery in Tumors”, Critical Reviews in Oncology/Hematology, 14: 29-39 (1992).
G. B. Dermer, “Another Anniversary for the War on Cancer”Bio/Technology, 12: 320 (1994).
T. Gura, “Systems for Identifying New Drugs are Often Faulty”,Science, 278: 1041-1042 (1997).
R.I. Freshney, “Culture of Animal Cells, A Manual of Basic Technique”,Department of Clinical Oncology, Cancer Research Campaign Laboratories, University Glasgow,pp. 3-4, 1983.
L H Hartwell, et al. “Integrating Genetic Approaches in the Discovery of Anticancer Drugs,”Science, 278: 1064-1068 (1997).
R K Jain, “Barriers to Drug Delivery in Solid Tumors”,Scientific American: 58-65 (1994).
“Extract from Endocrinology, Proceedings of the American Association for Cancer Research”, 36: 256 (1995).
Hohmann, et al. “Jatrophane Diterpenoids fromEuphorbia peplus”, Phytochemicstry, 51: 673-677 (1999).
Hohmann, et al. “Diterpenoids fromEuphorbia peplus”, Plant Med.66: 291-294 (2000).
Zayed, et al., Dietary risk from conditional cancerogens in produce of livestock fed on species of spurge (Euphorbiaceae) III. Milk of lactating goats fed on the skin irritant herb Eupho,J. Cancer Research&Clinical Oncolgy, 124(6): 301-306 (1998).
Zayed, et al., Dietary cancer risk conditional cancerogens in produce

Affiliated with

Also associated with

Rating

Anti-cancer compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-cancer compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4011225